News

July 13, 2022
Medical Research

Fulcrum Phase 3 FSHD Clinical Trial Using AMRA Medical’s Whole-body MRI Measurements as a Key Secondary Endpoint

REACH, a Phase 3 Clinical Trial of losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) utilizes AMRA’s Muscle Fat Infiltration (MFI) as a secondary endpoint. AMRA…
Read More
July 5, 2022
Medical Research

AMRA Medical continues to advance FSHD research with whole-body MRI measurements

AMRA’s recent publication demonstrates the utility of MRI-based muscle composite scores in neuromuscular disease clinical trials. AMRA Medical, a digital health company delivering a…
Read More
June 23, 2022
Medical Research

AMRA Biomarkers Indicate Individuals with CVD and T2D Have Faster Muscle Deterioration than Metabolically Disease-Free People — AMRA Medical to Present Data at SCWD

AMRA Medical will present “Two years of aging – initial results on changes in muscle composition in the UK Biobank imaging study” at SCWD,…
Read More
April 26, 2022
Medical Research

AMRA Medical’s MRI-based body composition measurements used in Lilly’s SURPASS-3 tirzepatide sub-study

Eli Lilly and Company assessed the impact of tirzepatide, an investigational therapy for the treatment of type 2 diabetes, on liver fat, visceral fat,…
Read More
March 24, 2022
Medical Research

AMRA Webinar: The Patient Experience Using MRI in DMD Clinical Trials – “Shed Light Through MRI”

Join us – with patients, industry leaders and a patient advocacy group to learn how to implement a magnetic resonance imaging (MRI) study designed…
Read More
March 14, 2022
Medical Research

AMRA Medical, Daiichi Sankyo and NCNP joint MRI-based muscle research accepted for poster presentation at 2022 MDA Conference

LINKÖPING, Sweden; March 14, 2022—AMRA’s recent research, performed in collaboration with Daiichi Sankyo and the National Center of Neurology and Psychiatry (NCNP) in Japan,…
Read More
February 14, 2022
Medical Research

AMRA Medical’s MRI data provide a unique opportunity for Pfizer’s GWAS

LINKÖPING, Sweden; February 14, 2022—One of the goals of AMRA’s collaboration with Pfizer and UK Biobank is to help identify and validate noninvasive biomarkers…
Read More
November 24, 2021
Medical Research

AMRA Medical Introduces Paradigm-shifting MRI Analysis Services at RSNA 2021

LINKÖPING, Sweden; November 24, 2021 – AMRA Medical will introduce two high-precision magnetic resonance imaging (MRI) analysis services for assessing body composition and muscle…
Read More
November 4, 2021
Medical Research

AMRA Images NMD – See Us at MYO-MRI Imaging in Neuromuscular Disease Conference 2021

MRI-whole body, whole muscles – precisely the answer   AMRA Medical invites you to meet at Virtual MYO MRI Imaging in Neuromuscular Disease Conference…
Read More
November 3, 2021
Medical Research

AMRA Medical’s AASLD Presentations – A Body Composition Research Quartet

LINKÖPING, Sweden; November 3, 2021—AMRA’s recent research using magnetic resonance imaging (MRI)-based body composition analysis on individuals with liver disease will be presented at…
Read More
By using our site, you acknowledge that you have read and understood our privacy policy. We use cookies to ensure you have the best browsing experience on our website.
Accept & Close